Eight-week mindfulness-based stress reduction reduced fatigue, anxiety, and depression in non-small cell lung cancer patients.

This randomized controlled trial investigated the effectiveness of an eight-week mindfulness-based stress reduction (MBSR) program in managing psychological and physical symptoms among patients with non-small cell lung cancer (NSCLC). The study population consisted of 80 patients who were undergoing surgery followed by adjuvant chemotherapy. Participants were randomized into two groups: one receiving the eight-week MBSR intervention and the other receiving standard care. The study setting and specific institutional details were not reported in the provided data. The primary outcomes assessed included fatigue, anxiety, and depression, while secondary outcomes focused on self-efficacy and mindfulness awareness. Follow-up assessments were conducted at one and three months post-intervention.

Regarding the primary outcome of fatigue, the MBSR group demonstrated significant improvements compared to the control group. These improvements were statistically significant with a p-value less than .05. The trajectory of fatigue scores indicated that levels peaked at the fourth week of the intervention. However, by the three-month follow-up, fatigue levels in the MBSR group had returned close to baseline. In contrast, the control group maintained elevated fatigue scores throughout the follow-up period. This suggests that while the intervention provided acute relief, the long-term maintenance of fatigue reduction may require ongoing engagement or alternative strategies.

For anxiety and depression, the results showed consistent and significant benefits for the intervention group. Anxiety scores decreased significantly in the MBSR group by the fourth week and continued to improve at subsequent time points. The statistical significance for anxiety was established with a p-value less than .01. Similarly, depression scores decreased significantly in the MBSR group by the fourth week and continued to improve. The reduction in depression scores also reached statistical significance with a p-value less than .01. These findings indicate that the MBSR program effectively addressed mood-related symptoms during the critical period following surgery and chemotherapy initiation.

Secondary outcomes revealed further benefits of the intervention. Self-efficacy showed consistent improvements in the MBSR group, with significant differences evident at both one and three months post-intervention. The statistical significance for self-efficacy was p < .01. Mindfulness awareness also demonstrated consistent improvements in the MBSR group, with significant differences evident at the same follow-up intervals. The significance for mindfulness awareness was also p < .01. These results suggest that the program successfully enhanced patients' sense of control and their awareness of present-moment experiences, which may contribute to better symptom management.

Safety and tolerability data were not reported in this study. There were no reported adverse events, serious adverse events, discontinuations, or specific tolerability metrics. Consequently, it is not possible to definitively state the safety profile based on the available evidence. However, the absence of reported adverse events suggests that the intervention was well-tolerated within the context of this trial. Clinicians should remain aware that safety data may be incomplete in small trials.

When compared to prior landmark studies in the therapeutic area of oncology supportive care, this study aligns with findings that suggest mindfulness interventions can alleviate distress. However, the specific population of NSCLC patients undergoing surgery and adjuvant chemotherapy represents a distinct subgroup. The study design is a randomized controlled trial, which provides a higher level of evidence than observational studies, but the sample size of 80 patients is relatively small. This limits the generalizability of the findings to larger or more diverse populations.

Key methodological limitations include the small sample size and the lack of reported safety data. The evidence in NSCLC populations remains limited, which is a noted limitation. Potential biases related to small sample sizes and the lack of blinding or detailed protocol descriptions cannot be fully excluded. The fact that fatigue benefits waned by three months suggests that the intervention effect may not be sustained without reinforcement. These factors must be considered when interpreting the results.

The clinical implications of this study support the integration of mindfulness-based interventions into routine care to improve patient well-being during and after treatment. For patients with NSCLC experiencing fatigue, anxiety, or depression, an eight-week MBSR program offers a potential non-pharmacologic option. The intervention appears particularly effective for mood symptoms and self-efficacy, with benefits persisting at three months. However, the transient nature of fatigue improvement suggests that clinicians should manage expectations regarding long-term symptom control. Future research should aim to address the limitations of small sample sizes and provide more comprehensive safety reporting.

Several questions remain unanswered. The long-term sustainability of benefits beyond three months is unclear. The optimal frequency and duration of mindfulness practice for maintaining gains are not defined. Furthermore, the specific mechanisms by which MBSR reduces fatigue in this population require further investigation. Clinicians should interpret these results with caution, recognizing that the evidence base for mindfulness in NSCLC is still developing. While the findings are promising, they should be integrated into a broader supportive care plan that includes other evidence-based interventions.